+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders

  • Book

  • June 2023
  • Elsevier Science and Technology
  • ID: 5755705

Overexpression of receptor tyrosine kinases (RTKs) has been implicated in cancer. Increasing evidence suggests that dysregulation of RTKs is reported in many neurodegenerative and psychiatric disorders.

Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders�provides a fundamental, pragmatic map of RTKs structure, activation, functions, mechanism of action, gene regulation, and signaling pathways in developing central nervous system (CNS), adult normal CNS, neurodegenerative and psychiatric disorders. Additionally, the structure, function, activation, and therapeutic potential of many growth factors have been covered. Here, international experts in the field offer a comprehensive discussion of results of pre-clinical and clinical studies of repositioning of anti-cancer receptor tyrosine kinase inhibitors�(RTKIs) and other promising protein kinase inhibitors in various neurodegenerative disorders including, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis, and psychiatric disorders including, anxiety, depression, alcohol use disorder, and schizophrenia. In addition, the book discusses the obstacles and opportunities for the potential repositioning of kinase inhibitors in neurodegenerative and psychiatric disorders.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. The Molecular Pathology of Neurodegenerative And Psychiatric Disorders 2. Receptor Tyrosine Kinases: An Overview 3. Roles of TRK Receptors, Tyrosine Kinase Receptors for Neurotrophins, in the Developing CNS 4. Receptor Tyrosine Kinase (RTKs): from biology to pathophysiology 5. Growth Factors and Their Receptors: Multitasking Functionality in Health and Disease 6. Regulation of Receptor Tyrosine Kinase Gene Expression 7. Role Of Receptor Tyrosine Kinases in Neurodegenerative Disorders 8. Insights into Receptor Tyrosine Kinase Signaling in Neurodegenerative Disorders: Opportunities and Translational Perspectives 9. Receptor Tyrosine Kinases in Major Depressive Disorder 10. Repositioning of Receptor Tyrosine Kinase Inhibitors: From Cancer to Neurodegenerative And Psychiatric Disorders 11. Protein Kinase Inhibitors as Therapeutics in Neurodegenerative and Psychiatric Disorders: Progress, Challenges, and Recommendations

Authors

Heba Mohamed Mansour Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-INN), Egyptian Drug Authority (EDA), Egypt.. Heba M. Mansour works at Central Administration of Biologicals, Innovative Products, and Clinical Studies (Bio-Inn), Egyptian Drug Authority (EDA). Heba is also pursuing her Ph.D. in pharmacology and toxicology at Faculty of Pharmacy, Cairo University. Her research interests lie in the potential repositioning of anti-cancer drugs especially kinase inhibitors in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. She has authored several articles, including research papers in prestigious international journals, book chapters, and review articles. Mahmoud Mohamed Khattab Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Prof. Dr. Mahmoud M. Khattab is emeritus professor of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University (FOPCU). Between 10-1994 to 12-1996, he was a Ph.D. Fellow in Nephrology Laboratory, at College of Medicine, Munster University, Munster, Germany. He worked as University Staff in Faculty of Pharmacy (2000-2006), and Faculty of Medicine (2008-2010), King Saud University, Riyadh, KSA. He joined German University in Cairo between 2006-2008. He worked as part-time staff in many Universities including Beni Suef University, 6 October University, and Ahram Canadian University. He has contributed to two postgraduate Diplomas at FOPCU, namely the Pharmacovigilance Diploma and IT-Based Clinical Toxicology Diploma. His current research interest includes RAS-based, and Tyrosine Kinase-based targeting therapies in neurodegenerative and musculoskeletal diseases. Management of chemotherapy-induced diseases including depression and neuropathy by repurposing of known pharmacological mechanisms is another area of interest. Furthermore, he has current research projects in Breast Cancer therapeutic-enhancing modalities, including nutritional one. Furthermore, He is a consultant member in many scientific committees at the Egyptian Drug Authority (EDA), including Pharmacovigilance, Cosmetic Products, Neuropsychiatry, Internal Medicine committees. Aiman Saad El-Khatib Vice President, Egyptian Drug Authority (EDA) and Professor of Pharmacology and Toxicology, Cairo University, Cairo, Egypt. Prof. Dr. Aiman Saad El-Khatib is currently the Vice President of the Egyptian Drug Authority. He is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He held several leadership positions in Cairo University including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in field of Theoretical and Applied Biological Sciences in 2004, Silver and Gold Medal of Merit from Egyptian Syndicate of Pharmacists in 2004 and 2005.